Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

129 trials

NCT06263491
Recruiting
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Phase 2 · United States · 1 site
Registry update: 10 Nov 2026
NCT06341556
Recruiting
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Phase 2 · China · 2 sites
Registry update: 4 Sept 2024
NCT05635162
Recruiting
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
Phase 2 · United Kingdom · 13 sites
Registry update: 16 Apr 2025
NCT06029309
Recruiting
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Phase 1/2 · United States · 1 site
Registry update: 21 Sept 2026
NCT06002659
Recruiting
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
Phase 1/2 · Sweden · 2 sites
Registry update: 10 Nov 2026
NCT06340737
Recruiting
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · United States · 1 site
Registry update: 12 Aug 2026
NCT06191887
Recruiting
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 1 · United States · 1 site
Registry update: 13 Feb 2026
NCT05887167
Recruiting
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Phase 1 · United States · 1 site
Registry update: 10 Aug 2026
NCT06482684
Recruiting
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
Phase 2 · Czechia, Germany, Spain, France, Netherlands · 42 sites
Registry update: 1 Jul 2024
NCT06045910
Recruiting
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Phase 1/2 · United Kingdom · 7 sites
Registry update: 28 Jul 2025
NCT06151730
Recruiting
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Not applicable · United States · 1 site
Registry update: 27 Feb 2026
NCT05910801
Recruiting
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 · United States · 2 sites
Registry update: 18 Nov 2024
NCT05868395
Recruiting
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Phase 2 · Austria · 1 site
Registry update: 29 May 2024
Conflicting statuses (not updated in the registry for 29 months)
2023-503206-37-00
Recruiting
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Phase 3 · Spain, France, Italy, Sweden · 17 sites
Registry update: 9 Sept 2026
NCT06136351
Recruiting
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2 · China · 1 site
Registry update: 29 Nov 2023
NCT06026319
Recruiting
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 · United States · 1 site
Registry update: 9 Oct 2026
NCT06084936
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Phase 3 · Australia, Brazil, Canada, China, Spain, France, United Kingdom, Italy, South Korea, Puerto Rico, Sweden, Taiwan, United States · 83 sites
Registry update: 5 Nov 2026
NCT05976763
Recruiting
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Phase 3 · United States · 242 sites
Registry update: 3 Nov 2026
NCT06022029
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Phase 1 · Australia, United States · 16 sites
Registry update: 24 Dec 2025
NCT05833763
Recruiting
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Phase 2 · Australia · 2 sites
Registry update: 8 Jan 2024

Ordered by registry start date. Freshness and sponsorship never change the order.